KalVista Secures FDA Approval for First-Ever Oral On-Demand HAE Treatment
KalVista Pharmaceuticals has achieved a significant milestone with the U.S. Food and Drug Administration’s (FDA) approval of its new oral therapy for hereditary angioedema (HAE), marking a breakthrough for patients…